Retinal vein occlusion (RVO) is a common vascular disorder with a prevalence of 0.7-1.56%.
vein occlusion). [3] [4] [5] Branch RVO (BRVO) occurs at arteriovenous crossing sites that share a common adventitia. 5 Central retinal vein occlusion (CRVO) is thought to be caused by external compression of the central retinal artery, which shares a common fibrous sleeve with the vein. 6 Visual handicap occurs due to macular oedema and neovascularisation, which are secondary to retinal ischaemia. [7] [8] [9] [10] [11] A number of inflammatory chemokines are thought to be involved in these processes and are found in elevated concentrations in the aqueous humour. Interleukin 6 (IL-6), IL-8, monocyte chemoattractant protein-1 (MCP-1), IL1-α, vascular endothelial growth factor (VEGF) and platelet-derived growth factor AA (PDGF-AA) are found to be elevated in CRVO. There are mixed results in terms of their concentrations in BRVO.
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Pathogenesis and Risk Factors
The pathogenesis of RVO is believed to follow the principles of Virchow's triad for thrombogenesis: vessel damage, stasis and hypercoagulability. 14 Contributing factors include: atherosclerosis, inflammatory disease and hypercoagulable/thrombophilia states. [15] [16] [17] A major risk factor for RVO is hypertension. [18] [19] [20] [21] [22] Dyslipidaemia is also a prevalent finding. 22 Associations have also been reported for diabetes mellitus, [18] [19] [20] [21] [22] renal disease, 23 cigarette smoking 18, 23 and thrombophilia. [16] [17] [18] [24] [25] [26] An additional ocular risk factor is glaucoma or elevated intraocular pressure (IOP), which may compromise retinal venous outflow. 18 More than 90% of cases of RVO occur in the >50 age group. 14 In patients >50 years of age a cardiovascular risk factor is usually present. In patients <50 years of age there is no obvious risk factor in up to 40% of cases.
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Natural History and Complications
The natural history for BRVO is variable but many patients have good prognosis. 29 One acceptable management option is follow-up without treatment as half of all patients may reach at least 20/40 vision within six months. 30 However, the BVOS study showed that only one-third of patients with macular oedema and vision of 20/40 or worse improved to better than 20/40 after three years with no intervention. 7 CRVO tends to have a worse visual prognosis, especially for the non-perfused form. 31 One-third of perfused CRVO may convert to non-perfused. 28 Neovascularisation may occur in 20% of non-perfused CRVO and 60% of those will develop neovascular glaucoma. 31 Initial visual acuity (VA) at presentation is a strong indicator of prognosis. The Despite a strong association with vascular disease, RVO does not appear to be an independent risk factor for death from cardiovascular causes. [32] [33] [34] However, a post-hoc analysis revealed an association among persons <70 years of age.
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Management
There are two aims in the management of RVO: the identification of modifiable risk factors and their medical management and the recognition and management of sight-threatening complications.
The current treatment options of RVO intend to minimise the damage, as there is no proven treatment to improve vision loss in the long term.
The therapy aims to prevent further visual loss and its complications, such as macular oedema, ischaemia or neovascularisation.
Medical Treatment
The 
Common Surgical Approaches to Retinal Vein Occlusion
There are several treatment strategies that focus on the surgical treatment of the occluded retinal vein, and they are summarised as follows.
Radial Optic Neurotomy
Increased pressure within the confined scleral outlet was hypothesised to cause thrombus at this location as a result of decreased lumen size and increased turbulence. Radial optic neurotomy (RON) was thought to release the pressure, increase the CRV lumen size and venous blood outflow and thus allow thrombosis clearance. 38 Moreover, RON was thought to induce the post-operative development of optociliary venous anastomosis or retinochoroidal shunts, leading to increased retinal venous outflow. [38] [39] [40] [41] [42] The technique 38 involved an incision on the nasal side of the optic nerve, radial to the nerve and parallel to the nerve fibre layer.
Although RON has been proposed as safe by most authors, the possibility of serious complications should not be overlooked.
The procedure carries a potential risk of laceration of the central retinal artery or CRV, optic nerve fibre damage with visual field loss, globe perforation, retinal detachment, choroidal neovascularisation at the neurotomy site and anterior segment neovascularisation. 38, [43] [44] [45] Careful patient selection may provide better results after RON. Patients with pronounced peripapillary swelling at baseline and with an onset of CRVO of <90 days were reported to be more likely to benefit from RON. 42 As a result, the benefits of RON appear to be controversial and its efficacy remains to be proved in prospective randomised clinical studies.
Chorioretinal Venous Anastomosis
Chorioretinal 61 In another study, a disappointing visual outcome Current Treatment of Retinal Vein Occlusion 
Arteriovenous Sheathotomy
The surgical procedure includes PPV with posterior hyaloid detachment for the treatment of BVO. 64 The end-point of surgery is elevation and separation of the arteriole from the underlying venule confirmed using a subretinal spatula.
Until now, most studies of arteriovenous sheathotomy (AVS) have been uncontrolled and have failed to show a convincing improvement in outcomes of BRVO that would justify the risks of the surgical procedure.
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Steroids
The rationale for the use of intravitreal steroids to treat macular oedema is that corticosteroids reduce retinal capillary permeability and angiogenesis, targeting cytokines such as IL-1b, inter-cellular adhesion molecule 1 (ICAM-1) and VEGF.
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Triamcinolone Acetonide
Intravitreal triamcinolone for RVO was first described in case reports in 2002. 73 Evaluation of responses to treatment with a range of doses (4-25mg) show short-lived responses. Therefore, for effective treatment it appears that more than one injection is usually needed.
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The phase III multicentre Standard care vs. corticosteroid for retinal vein occlusion (SCORE) CRVO study evaluated a preservative-free form of intravitreal triamcinolone acetonide (IVTA) injection administered every four months (TRIVARIS, Allergan). 75 The groups were divided into 1mg, 4mg IVTA or observation groups; the results showed that both doses of TRIVARIS produced both anatomical and functional improvement of macular oedema due to CRVO compared with observation. However, at month 12, the 1mg dose had a better safety profile compared with the 4mg dose in terms of a lower incidence of raised IOP >35mmHg (2%, 14 versus 1% for observation), incidence of cataract formation or progression (25 versus 35%, versus 13%) and need for cataract surgery (0%, 4 versus 3%). As such, laser is considered to have a more favourable risk:benefit profile to TRIVARIS in CRVO.
The SCORE-BRVO 76,77 study evaluated the efficacy of different doses of TRIVARIS compared with laser photocoagulation for macular oedema secondary to BRVO. The results showed that both doses of TRIVARIS produced both anatomical and functional improvement, but this was similar in magnitude to laser. In addition, at month 12, both the 1 and 4mg doses had an inferior safety profile compared with laser in terms of a higher incidence of raised IOP (2 and 14%, versus 1%), incidence of cataract formation or progression (25 and 35%, versus 13%) and need for cataract surgery (0 and 4%, versus 3%) As such, laser is considered to have a more favourable benefit to risk profile to TRIVARIS in BRVO.
TRIVARIS is US Food and Drug Administration (FDA) approved, but
is not currently widely available clinically. 78 There is no evidence to suggest that the visual and anatomical responses seen with TRIVARIS in SCORE-BRVO would be replicated with off-label IVTA preparations such as KENALOG or TRIESENCE.
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Dexamethasone Biodegradeable Implant
The short half-life of intravitreal dexamethasone suggested that its use is limited in the management of chronic and/or recurrent macular oedema. 82 This led to the development of biodegradable, sustained-release, intravitreal implants containing dexamethasone.
They were shown to increase the duration of action of dexamethasone in rabbit eyes. 83 Ozurdex ( Subanalyses from GENEVA also suggest that treating RVO patients with shorted duration of macular oedema results in better outcome for VA. Delaying treatment leads to a reduced possibility to gain significant vision. 85 Based on the GENEVA study programme, OZURDEX has received FDA and EU approval for the 0.7mg preparation and is licensed in the UK for the treatment of adult patients with macular oedema secondary to either BRVO or CRVO (OZURDEX SmPC).
86
Other Sustained-release Implants
The Verisome ® drug-delivery system is an extended-release, biodegradable implant that is inserted into the eye with a 30G
needle. IBI-20089 is based on this technology and is a novel triamcinolone slow-release insert that is designed to last up to one year with a single intravitreal injection. A phase I multicentre trial study evaluated the efficacy of this drug in patients with chronic cystoid oedema due to RVO. Two doses were investigated (6.9mg triamcinolone in 25μl and 13.8mg triamcinolone in 50μl). The study showed a good safety profile with decreased central retinal thickness.
A 13.8mg dose was found to be more effective than 6.9mg. 87 Retisert is a fluocinolone acetonide (FA) implant, which releases 0.59 or 2.1mg
FA. It is currently in use for non-infectious posterior uveitis. [88] [89] [90] It has also been tested in patients with macular oedema secondary to CRVO, achieving an improvement in VA and a reduction of the macular oedema at 12 months. 91 However, implanted eyes had higher incidences of IOP elevation and cataracts. 88, 90, 91 Iluvien is a smaller device, that releases 0.2 or 0.5mcg/day of FA and has been investigated for the treatment of diabetic macular oedema with promising results. 92 
Anti-vascular Endothelial Growth Factor Treatments
Concentrations of VEGF and IL-6 are significantly elevated in the aqueous humour of patients with retinal ischaemia. [93] [94] [95] These factors have been shown to increase vascular permeability and angiogenesis 96 and correlate with the severity of macular oedema and VA loss. 94, 95, 97 This finding is the basis for anti-VEGF therapy in vein occlusions.
Bevacizumab (Avastin)
There are several retrospective and prospective studies showing improved VA and decreased macular oedema with intravitreal bevacizumab. [98] [99] [100] [101] [102] [103] [104] [105] However, the effect is usually transient (lasting six to eight weeks) and multiple injections are often needed. 93, 98, 106 Most studies show no difference in overall outcome between 1 and 2.5mg
doses. 98,100,101,107-113 Ach et al. observed that CRVO patients who benefited from treatment were significantly younger, with lower central retinal thickness at baseline for CRVO. However, these predictive factors were not found for BRVO patients. 114 Intravitreal bevacizumab has also been successfully used in RVO for reversing iris neovascularisation. 115 Bevazicumab may be an important therapy for patients not responsive to other treatments. Rabena et al. reported 27 cases improving with 1.25mg/ml bevacizumab. More than 80% of these patients had been unresponsive to prior laser or intravitreal steroid treatment. 101 No significant complications have been reported with this treatment modality although there is a lack of long-term follow-up data. . Serious side effects were also rare in this study. 121 Overall, both studies showed a significant improvement in VA in the ranibizumab group versus the control group with low rates of adverse side effects. 96, 97 These trials also highlighted that delaying treatment was still superior to no treatment. 122 
Pegaptanib Sodium (Macugen)
This drug is a pegylated anti-VEGF aptamer that specifically binds to VEGF165 There are limited small-scale studies investigating the effects of this drug for RVO, with promising results. To date, anti-VEGF treatments have shown to increase likelihood of VA gain with minimal side effects. However, a high injection rate is often necessary and there is no definitive therapeutic scheme. Often, there is a rebound effect of increased macular oedema after an initial decrease, which may be due to upregulation of VEGF receptors.
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Approximately one-third of patients do not improve with treatment. 127 These patients have been shown to have higher aqueous levels of VEGF and tend to be associated with ischaemic RVO. intravitreal triamcinlone initial dose. 138 The intravitreal avastin versus intravitreal avastin and triamcinolone in CRVO is also listed on the ClinicalTrials.org website. 139 To date, no results from this study have been published.
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E U R O P E A N O P H T H A L M I C R E V I E W
Surgical/Medical Treatment
The benefit of combined vitrectomy (with or without internal limiting membrane peeling) with IVTA is unclear. [140] [141] [142] Promising results have been described for triple therapy with IVTA, bevacizumab and vitrectomy. 153 However, there is a lack of large, multicentre, randomised controlled trials to support these results.
Conclusion
The currently recommended treatment of RVO consists of identifying and managing cardiovascular risk factors and retinal laser therapy. 
